Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy

BACKGROUND: Metabolic and energy disorders are considered central to the etiology of diabetic cardiomyopathy (DCM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) can effectively reduce the risk of cardiovascular death and heart failure in patients with DCM. However, the underlying mechanism has...

Descripción completa

Detalles Bibliográficos
Autores principales: Xi, Yangbo, Chen, Dongping, Dong, Zhihui, Zhang, Jinhua, Lam, Hingcheung, He, Jiading, Du, Keyi, Chen, Can, Guo, Jun, Xiao, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579694/
https://www.ncbi.nlm.nih.gov/pubmed/36277768
http://dx.doi.org/10.3389/fcvm.2022.999254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579694/
https://www.ncbi.nlm.nih.gov/pubmed/36277768
http://dx.doi.org/10.3389/fcvm.2022.999254

Ejemplares similares